Gut microbiota and gastrointestinal tumors: insights from a bibliometric analysis

TL;DR

This paper uses bibliometric analysis to explore research trends in gut microbiota's role in gastrointestinal tumor treatment, highlighting key contributors and emerging topics.

Contribution

The study provides a comprehensive bibliometric overview of gut microbiota research in gastrointestinal tumors, identifying growth areas and key players.

Findings

China and the United States are leading in research output on gut microbiota and gastrointestinal tumors.

Emerging research frontiers include immunotherapy, drug delivery, and tumorigenesis.

Hannah R. Wardill is the most prolific author in the field.

Abstract

Despite the growing number of studies on the role of gut microbiota in treating gastrointestinal tumors, the overall research trends in this field remain inadequately characterized.

A bibliometric analysis was conducted using publications retrieved from the Web of Science Core Collection (up to September 30, 2024). Analytical tools including VOSviewer, CiteSpace, and an online bibliometric platform were employed to evaluate trends and hotspots.

Analysis of 1,421 publications revealed significant geographical disparities in research output, with China and the United States leading contributions. Institutionally, the University of Adelaide, Zhejiang University, and Shanghai Jiao Tong University were prominent contributors. Authorship analysis identified Hannah R. Wardill as the most prolific author, while the International Journal of Molecular Sciences emerged as a leading journal. Rapidly growing frontiers include “proliferation,” “inhibition,” “immunotherapy,” “drug delivery,” and “tumorigenesis.”

This study provides a comprehensive overview of research trends and highlights emerging directions, aiming to advance scientific and clinical applications of gut microbiota in gastrointestinal tumor therapy.

Figures